Literature DB >> 18503580

Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient.

Thet Thet Lin1, Saman Hewamana, Rachel Ward, Hannah Taylor, Tammy Payne, Guy Pratt, Duncan Baird, Chris Fegan, Chris Pepper.   

Abstract

In agreement with a recently published manuscript, this present study demonstrated that CD38+ sub-populations had increased proliferative activity as evidenced by higher Ki-67 expression (P < 0.0001). This raised the possibility that the CD38+ fraction is exposed to an increased risk of clonal evolution. However, serial fluorescence in situ hybridisation analysis of highly purified CD38+ and CD38- sub-populations from individual patients revealed no distinct cytogenetic lesions or evidence of preferential clonal evolution in the CD38+ fractions when compared with their CD38- counter-parts (P = 0.13). Furthermore, telomere length analysis revealed that all of the sub-populations had similarly short telomeres (P = 0.31) and comparably low telomerase (TERT) expression (P = 0.75) and telomerase activity (P = 0.88). Subsequent examination of cell-sorted CD38+ and CD38- sub-populations from paired peripheral blood and bone marrow samples taken on the same day showed no significant difference in CD38, Ki-67, TERT expression or telomere lengths, indicating that these chronic lymphocytic leukaemia cells were derived from a single pool trafficking between these two compartments. Taken together, our data show that chronic lymphocytic leukaemia cells derived from bimodal patients all have extensive proliferative histories and have undergone a similar number of cell divisions that is mirrored by the episodic expression of CD38.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503580     DOI: 10.1111/j.1365-2141.2008.07236.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Probing the mitotic history and developmental stage of hematopoietic cells using single telomere length analysis (STELA).

Authors:  Mark Hills; Kai Lücke; Elizabeth A Chavez; Connie J Eaves; Peter M Lansdorp
Journal:  Blood       Date:  2009-04-09       Impact factor: 22.113

Review 2.  CD38 and chronic lymphocytic leukemia: a decade later.

Authors:  Fabio Malavasi; Silvia Deaglio; Rajendra Damle; Giovanna Cutrona; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

3.  CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells.

Authors:  Silvia Deaglio; Semra Aydin; Maurizia Mello Grand; Tiziana Vaisitti; Luciana Bergui; Giovanni D'Arena; Giovanna Chiorino; Fabio Malavasi
Journal:  Mol Med       Date:  2009-11-20       Impact factor: 6.354

4.  In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia.

Authors:  Carlo Calissano; Rajendra N Damle; Gregory Hayes; Elizabeth J Murphy; Marc K Hellerstein; Carol Moreno; Cristina Sison; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2009-09-29       Impact factor: 22.113

5.  p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia.

Authors:  M J Groves; C E Johnson; J James; A R Prescott; J Cunningham; S Haydock; C Pepper; C Fegan; L Pirrie; N J Westwood; P J Coates; I G Ganley; S Tauro
Journal:  Br J Cancer       Date:  2013-10-03       Impact factor: 7.640

6.  CD38 Multi-Functionality in Oral Squamous Cell Carcinoma: Prognostic Implications, Immune Balance, and Immune Checkpoint.

Authors:  Zhuang Ding; Yijia He; Yong Fu; Nisha Zhu; Mengxiang Zhao; Yuxian Song; Xiaofeng Huang; Sheng Chen; Yan Yang; Caihong Zhang; Qingang Hu; Yanhong Ni; Liang Ding
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244

Review 7.  The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.

Authors:  Gabriele Brachtl; Josefina Piñón Hofbauer; Richard Greil; Tanja Nicole Hartmann
Journal:  Ann Hematol       Date:  2013-11-28       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.